Clinical trials: Any Cancer
Advanced Solid Tumor
Study to Evaluate the Safety and Tolerability of ABL501, and to Determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of ABL501 in Subjects With Any Progressive, Locally Advanced (Unresectable) or Metastatic Solid Tumors
This is a first-in-human (FIH) phase 1 open-label, multicenter, multiple-dose, dose-escalation and dose-expansion study of ABL501 to evaluate the safety, tolerability, MTD and/or RP2D, PK, immunogenicity, preliminary anti-tumor…
- Trial name
- NCT05101109
- Testing
- ABL501
- Where
- 4 sites in South Korea
- Volunteers
- 24 people
- Sponsor
- ABL Bio, Inc.
Non Clear Cell Renal Cell Carcinoma (nccRCC)
A Trial to Evaluate Efficacy and Safety of Lenvatinib in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Non Clear Cell Renal Cell Carcinoma (nccRCC) Who Have Not Received Any Chemotherapy for Advanced Disease
This is a single-arm, multicenter, Phase 2 study of lenvatinib in combination with everolimus in participants with unresectable advanced or metastatic non clear cell renal cell carcinoma (nccRCC) who have not received any…
- Trial name
- NCT02915783
- Testing
- lenvatinib, everolimus
- Where
- 8 sites in United States
- Volunteers
- 41 people
- Sponsor
- Eisai Inc.
Breast Cancer
Vepdegestrant (ARV-471/PF-07850327) + Palbociclib vs Letrozole + Palbociclib in ER(+)/HER2(-) Advanced Breast Cancer
The purpose of this study is to understand the safety and effects of the study medicine vepdegestrant (ARV-471/PF-07850327) given together with palbociclib in advanced breast cancer.
- Trial name
- VERITAC-3 (NCT05909397)
- Testing
- Vepdegestrant (ARV-471/PF-07850327), Palbociclib, Letrozole
- Where
- 29 sites in United States, Australia and 8 more
- Volunteers
- 59 people
- Sponsor
- Pfizer
Advanced Solid Tumor
A Study With ABL103 in Subjects With Advanced or Metastatic Solid Tumors
This is a first-in-human Phase 1, single-arm, open-label, multicenter, multiple-dose, dose-escalation study of ABL103 to evaluate the safety, tolerability, MTD (maximum tolerated dose) and/or RP2D (recommended phase 2 dose)…
- Trial name
- NCT06126666
- Testing
- ABL103
- Where
- 3 sites in South Korea
- Volunteers
- 96 people
- Sponsor
- ABL Bio, Inc.
Non-Small Cell Lung Cancer, Medullary Thyroid Cancer
A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)
This is an open-label, first-in-human study designed to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary anti-tumor activity of selpercatinib (also known as LOXO-292) administered orally to participants…
- Conditions
- Non-Small Cell Lung Cancer, Medullary Thyroid Cancer, Colon Cancer, Any Solid Tumor
- Trial name
- LIBRETTO-001 (NCT03157128)
- Testing
- LOXO-292
- Where
- 85 sites in United States, Australia and 14 more
- Volunteers
- 857 people
- Sponsor
- Eli Lilly and Company
Carcinoma, Hepatocellular
GIDEON Non-Nexavar Arm - HCC Patients Who Are Treated With Any Therapy Other Than Nexavar at Individual Study Start
This study is an international prospective, open-label, multi-center, non-interventional study. The protocol will allow enrollment of all patients with diagnosis of HCC in whom a decision to treat with sorafenib has not been made…
- Trial name
- NCT01191385
- Testing
- Any treatment for unresectable HCC as chosen by the physician
- Where
- 24 sites in United States
- Sponsor
- Bayer
Solid Tumor, Tumors of Any Histology With Activating Trk (NTRK) Point or NTRK Fusion Mutations
Phase 1 Study of PLX7486 as Single Agent in Patients With Advanced Solid Tumors
The objective of this study is to determine the safety, pharmacokinetics, maximum tolerated dose/recommended Phase 2 dose, and efficacy of PLX7486.
- Conditions
- Solid Tumor, Tumors of Any Histology With Activating Trk (NTRK) Point or NTRK Fusion Mutations, Tenosynovial Giant Cell Tumor
- Trial name
- NCT01804530
- Testing
- PLX7486 TsOH
- Where
- 4 sites in United States
- Volunteers
- 59 people
- Sponsor
- Plexxikon
Candidiasis, Oral, Thrush
Novel Rinse to Treat in Oral Candidiasis in Cancer Patients
The purpose of the study is to evaluate the efficacy of Iocide oral rinse as a treatment for Oral Candidiasis in any patient including but not limited to patients receiving radiation therapy or who have previously received…
- Conditions
- Candidiasis, Oral, Thrush, Candidiasis
- Trial name
- NCT00612963
- Testing
- Frio Oral Rinse
- Where
- 2 sites in United States
- Volunteers
- 23 people
- Sponsor
- Biomedical Development Corporation
Hypercalcemia of Malignancy, Lung Cancer
Zoledronate in Treating Patients With Solid Tumors That Have Spread to the Bone
RATIONALE: Zoledronate may help to relieve some of the symptoms caused by bone metastases. It is not yet known if zoledronate is more effective than no further therapy in relieving symptoms of bone metastases or preventing…
- Conditions
- Hypercalcemia of Malignancy, Lung Cancer, Metastatic Cancer, Pain
- Trial name
- NCT00003884
- Testing
- zoledronic acid, quality-of-life assessment
- Where
- 55 sites in United States
- Volunteers
- 600 people
- Sponsor
- Novartis
Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL)
A Study to Assess Long-term Safety of Tazemetostat in Adult Participants of All Ages With Any Disease Treated With Tazemetostat in a Previous Clinical Study
This study will provide continuing availability to tazemetostat for people that have previously completed participation in a tazemetostat study, either with monotherapy (single drug treatment) or combination therapy.
- Conditions
- Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), Synovial Sarcoma, Epithelioid Sarcoma (ES)
- Trial name
- TRuST (NCT02875548)
- Testing
- Tazemetostat
- Where
- 34 sites in United States, Australia and 5 more
- Volunteers
- 58 people
- Sponsor
- Epizyme, Inc.
Chronic Myeloid Leukemia
Nilotinib for Patients With Chronic Myeloid Leukemia in First Line and Any Subsequent Line
This was a non-interventional observational study within the routine chronic myeloid leukemia treatment practice; no further tests were required apart from the assessments routinely performed for Chronic myeloid leukemia patients…
- Trial name
- NOFRETETE (NCT05734053)
- Testing
- Nilotinib
- Where
- 77 sites in Germany
- Volunteers
- 222 people
- Sponsor
- Novartis Pharmaceuticals
Head and Neck Cancer
Postoperative Radiotherapy Plus Iressa or Radiotherapy Plus Cisplatin and Iressa for Advanced Head & Neck Cancer
To evaluate the feasibility and safety of (cohort 1) postoperative standard fractionation radiotherapy plus Iressa and of (cohort 2) hyperfractionated radiotherapy plus cisplatin and Iressa
- Trial name
- IRESSA&H&N (NCT00681967)
- Testing
- Gefitinib
- Where
- 2 sites in Switzerland
- Volunteers
- 30 people
- Sponsor
- AstraZeneca
Malignant Rhabdoid Tumors (MRT), Rhabdoid Tumors of the Kidney (RTK)
A Study of Tazemetostat in Adult Participants With Soft Tissue Sarcoma
This study will include participants with various types of cancer known as soft-tissue sarcomas. Tissues that can be affected by soft tissue sarcomas include fat, muscle, blood vessels, deep skin tissues, tendons and ligaments.
- Conditions
- Malignant Rhabdoid Tumors (MRT), Rhabdoid Tumors of the Kidney (RTK), Atypical Teratoid Rhabdoid Tumors (ATRT), Selected Tumors With Rhabdoid Features
- Trial name
- NCT02601950
- Testing
- Tazemetostat
- Where
- 32 sites in United States, Australia and 7 more
- Volunteers
- 267 people
- Sponsor
- Epizyme, Inc.
Solid Tumor, Adult, Tumor, Solid
AD1208 in Subjects With Any Progressive, Locally Advanced or Metastatic Solid Tumors
The goal of this clinical trial is to evaluate the safety and tolerability of AD1208 to determine the maximum tolerated dose(MTD) or maximumly administered dose(MAD) in any progressive, locally advanced (unresectable) or…
- Conditions
- Solid Tumor, Adult, Tumor, Solid, Solid Tumor, Solid Tumor, Unspecified, Adult
- Trial name
- AD1208 (NCT06911333)
- Testing
- AD1208
- Where
- 3 sites in South Korea
- Volunteers
- 36 people
- Sponsor
- Avelos Therapeutics Inc.
Acute Myeloid Leukemia (AML)
Study of Oral Venetoclax Tablets to Evaluate Adverse Events and Change in Disease Activity in Participants of Any Age With Acute Myeloid Leukemia
Acute Myeloid Leukemia (AML) is an aggressive and rare cancer of myeloid cells (a white blood cell responsible for fighting infections) and is the most common acute leukemia in adults.
- Trial name
- NCT04813263
- Where
- 281 sites in Japan
- Volunteers
- 424 people
- Sponsor
- AbbVie
Any Advanced Solid Tumors, Triple Negative Breast Cancer
NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors
The main purposes of Phase 1b of this study are to determine the following in participants with advanced solid tumors: Safety and tolerability of NT-I7 in combination with pembrolizumab Maximum Tolerated Dose (MTD) and/or the…
- Conditions
- Any Advanced Solid Tumors, Triple Negative Breast Cancer, Non Small Cell Lung Cancer, Small Cell Lung Cancer
- Trial name
- NCT04332653
- Testing
- NT-I7, pembrolizumab (KEYTRUDA®)
- Where
- 8 sites in United States
- Volunteers
- 215 people
- Sponsor
- NeoImmuneTech
Any Tumor Type Eligible for Treatment With Talimogene Laherparepvec in Amgen or BioVEX-sponsored Clinical Trial
Registry Study for Talimogene Laherparepvec
A Registry Study to Evaluate the Survival and Long-Term Safety of Subjects Who Previously Received Talimogene Laherparepvec in Amgen or BioVEX-Sponsored Clinical Trials
- Trial name
- NCT02173171
- Testing
- Information collection
- Where
- 59 sites in United States, Austria and 13 more
- Volunteers
- 185 people
- Sponsor
- Amgen
Chronic Myeloid Leukemia
Observational Study on CML Patients in Any Phase of the Disease Treated With Ponatinib (Iclusig®)
This is a multicentre ambispective cohort study involving French patients who have started or are receiving for less than 6 months a treatment with ponatinib.
- Trial name
- NCT04048564
- Where
- 40 sites in France
- Volunteers
- 120 people
- Sponsor
- Incyte BioSciences France
Breast Neoplasms
A Study of Palbociclib (PD-0332991) + Letrozole vs. Letrozole For 1st Line Treatment Of Postmenopausal Women With ER+/HER2- Advanced Breast Cancer (PALOMA-2)
The study is designed to compare the clinical benefit following treatment with letrozole in combination with PD-0332991 versus letrozole in combination with placebo in postmenopausal women with ER(+)/HER2(-) advanced breast…
- Trial name
- NCT01740427
- Testing
- PD-0332991, Letrozole
- Where
- 305 sites in United States, Australia and 16 more
- Volunteers
- 666 people
- Sponsor
- Pfizer
Myeloid Leukemia, Chronic, Chronic-Phase
Treating Patients With Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) With Dasatinib
CML requires ongoing treatment and assessment of treatment milestones in order to manage the disease properly. Dasatinib is approved for the treatment of newly diagnosed PH+ CP-CML and CML in chronic or accelerated phase or blast…
- Trial name
- DasPAQT (NCT02348957)
- Where
- 66 sites in Germany
- Volunteers
- 223 people
- Sponsor
- Onco Medical Consult GmbH